Verrica Pharmaceuticals/$VRCA
Verrica Pharmaceuticals shares are trading higher after amending its collaboration with Torii Pharmaceutical, including a global Phase 3 trial and an $8 million milestone payment.
19 hours ago·Lightyear AI
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Ticker
$VRCA
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
71
ISIN
US92511W1080
Website
VRCA Metrics
BasicAdvanced
$60M
-
-$1.03
1.74
-
Price and volume
Market cap
$60M
Beta
1.74
52-week high
$8.98
52-week low
$0.38
Average daily volume
493K
Financial strength
Current ratio
1.343
Quick ratio
1.199
Long term debt to equity
-155.922
Total debt to equity
-228.429
Interest coverage (TTM)
-5.87%
Profitability
EBITDA (TTM)
-53.734
Gross margin (TTM)
-56.22%
Net profit margin (TTM)
-919.21%
Operating margin (TTM)
-760.09%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-62.87%
Return on equity (TTM)
773.26%
Valuation
Price to revenue (TTM)
5.77
Price to book
-3.2
Price to tangible book (TTM)
-3.2
Price to free cash flow (TTM)
-0.772
Free cash flow yield (TTM)
-129.60%
Free cash flow per share (TTM)
-84.02%
Growth
Revenue change (TTM)
-19.45%
Earnings per share change (TTM)
-40.89%
3-year revenue growth (CAGR)
155.39%
3-year earnings per share growth (CAGR)
-12.68%
What the Analysts think about VRCA
Analyst ratings (Buy, Hold, Sell) for Verrica Pharmaceuticals stock.
VRCA Financial Performance
Revenues and expenses
VRCA Earnings Performance
Company profitability
VRCA News
AllArticlesVideos

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
GlobeNewsWire·3 days ago

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
GlobeNewsWire·1 month ago

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Verrica Pharmaceuticals stock?
Verrica Pharmaceuticals (VRCA) has a market cap of $60M as of July 04, 2025.
What is the P/E ratio for Verrica Pharmaceuticals stock?
The price to earnings (P/E) ratio for Verrica Pharmaceuticals (VRCA) stock is 0 as of July 04, 2025.
Does Verrica Pharmaceuticals stock pay dividends?
No, Verrica Pharmaceuticals (VRCA) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Verrica Pharmaceuticals dividend payment date?
Verrica Pharmaceuticals (VRCA) stock does not pay dividends to its shareholders.
What is the beta indicator for Verrica Pharmaceuticals?
Verrica Pharmaceuticals (VRCA) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.